23809138|t|Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy.
23809138|a|BACKGROUND: Atrial fibrillation (AF) is associated with increased mortality and morbidity, including risk for cerebral macro- and microinfarctions and cognitive decline, even in the presence of adequate oral anticoagulation. AF is strongly related to increased inflammatory activity whereby anti-inflammatory agents can reduce the risk of new or recurrent AF. However, it is not known whether anti-inflammatory therapy can also modify the deterioration of neurocognitive function in older patients with AF. In the present study, older patients with AF were treated with intensive lipid-lowering therapy with atorvastatin 40 mg and ezetimibe 10 mg, or placebo. We examined the relationship between neurocognitive functions and inflammatory burden. FINDINGS: Analysis of inflammatory markers revealed significant reductions in high sensitivity C-reactive protein (hs-CRP), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1 receptor antagonist (IL-1RA), interleukin (IL)-9, IL-13 and IL-17, and interferon-gamma (IFNgamma) in the treatment group compared to placebo. Reduction in plasma concentration of IL-1RA, IL-2, IL-9 and IL-12, and macrophage inflammatory protein-1beta (MIP-1beta) correlated significantly with improvement in the neurocognitive functions memory and speed. Loss of volume in amygdala and hippocampus, as determined by magnetic resonance imaging (MRI), was reduced in the treatment arm, statistically significant for left amygdala. CONCLUSIONS: Anti-inflammatory therapy through intensive lipid-lowering treatment with atorvastatin 40 mg and ezetimibe 10 mg can modify the deterioration of neurocognitive function, and the loss of volume in certain cerebral areas in older patients with AF. TRIAL REGISTRATION ClinicalTrials.gov: NCT00449410.
23809138	57	69	inflammatory	Disease	MESH:D007249
23809138	80	99	atrial fibrillation	Disease	MESH:D001281
23809138	100	108	patients	Species	9606
23809138	132	143	cholesterol	Chemical	MESH:D002784
23809138	174	193	Atrial fibrillation	Disease	MESH:D001281
23809138	195	197	AF	Disease	MESH:D001281
23809138	313	330	cognitive decline	Disease	MESH:D003072
23809138	387	389	AF	Disease	MESH:D001281
23809138	423	435	inflammatory	Disease	MESH:D007249
23809138	458	470	inflammatory	Disease	MESH:D007249
23809138	518	520	AF	Disease	MESH:D001281
23809138	560	572	inflammatory	Disease	MESH:D007249
23809138	601	641	deterioration of neurocognitive function	Disease	MESH:D019965
23809138	651	659	patients	Species	9606
23809138	665	667	AF	Disease	MESH:D001281
23809138	697	705	patients	Species	9606
23809138	711	713	AF	Disease	MESH:D001281
23809138	742	747	lipid	Chemical	MESH:D008055
23809138	770	782	atorvastatin	Chemical	MESH:D000069059
23809138	793	802	ezetimibe	Chemical	MESH:D000069438
23809138	888	900	inflammatory	Disease	MESH:D007249
23809138	931	943	inflammatory	Disease	MESH:D007249
23809138	1004	1022	C-reactive protein	Gene	1401
23809138	1027	1030	CRP	Gene	1401
23809138	1065	1102	granulocyte colony-stimulating factor	Gene	1440
23809138	1104	1109	G-CSF	Gene	1440
23809138	1112	1160	granulocyte-macrophage colony-stimulating factor	Gene	1437
23809138	1162	1168	GM-CSF	Gene	1437
23809138	1171	1204	interleukin-1 receptor antagonist	Gene	3557
23809138	1206	1212	IL-1RA	Gene	3557
23809138	1215	1233	interleukin (IL)-9	Gene	3578
23809138	1235	1240	IL-13	Gene	3596
23809138	1245	1250	IL-17	Gene	3605
23809138	1256	1272	interferon-gamma	Gene	3458
23809138	1274	1282	IFNgamma	Gene	3458
23809138	1365	1371	IL-1RA	Gene	3557
23809138	1373	1377	IL-2	Gene	3558
23809138	1379	1383	IL-9	Gene	3578
23809138	1388	1393	IL-12	Gene	3593
23809138	1399	1436	macrophage inflammatory protein-1beta	Gene	6351
23809138	1438	1447	MIP-1beta	Gene	6351
23809138	1541	1555	Loss of volume	Disease	MESH:D016388
23809138	1733	1745	inflammatory	Disease	MESH:D007249
23809138	1772	1777	lipid	Chemical	MESH:D008055
23809138	1802	1814	atorvastatin	Chemical	MESH:D000069059
23809138	1825	1834	ezetimibe	Chemical	MESH:D000069438
23809138	1856	1896	deterioration of neurocognitive function	Disease	MESH:D019965
23809138	1906	1920	loss of volume	Disease	MESH:D016388
23809138	1956	1964	patients	Species	9606
23809138	1970	1972	AF	Disease	MESH:D001281
23809138	Association	MESH:D007249	3557
23809138	Negative_Correlation	MESH:D008055	MESH:D001281
23809138	Negative_Correlation	MESH:D000069438	MESH:D001281
23809138	Association	MESH:D007249	3596
23809138	Association	MESH:D001281	1401
23809138	Negative_Correlation	MESH:D000069059	MESH:D007249
23809138	Association	MESH:D000069438	MESH:D019965
23809138	Association	MESH:D007249	3458
23809138	Association	MESH:D000069059	MESH:D019965
23809138	Association	MESH:D007249	1440
23809138	Negative_Correlation	MESH:D000069059	MESH:D001281
23809138	Association	MESH:D007249	3605
23809138	Positive_Correlation	MESH:D000069059	MESH:D016388
23809138	Association	MESH:D007249	3578
23809138	Association	MESH:D007249	1401
23809138	Positive_Correlation	MESH:D000069438	MESH:D016388
23809138	Negative_Correlation	MESH:D000069059	MESH:D008055
23809138	Negative_Correlation	MESH:D000069438	MESH:D007249
23809138	Association	MESH:D007249	1437

